Although initial concerns regarding rates of clinically relevant cardiac complications associated with Herceptin-based therapy have largely been eased, physicians remain cautious about administration of Herceptin in terms of potential cardiac issues. Continued analysis of data regarding the association between Herceptin and cardiac health is ongoing in order to provide additional information that will aid in appropriate monitoring and further ease concerns regarding this issue.
Headline News Archive
Click on title to read the full article.
Looking to Refine HER2-targeted Therapy
January 14, 2021
By NCI - National Cancer Institute
When is a patient a candidate for a targeted therapy? That’s a question some breast cancer researchers are attempting to answer in the wake of results from several studies presented in 2007 that suggested the definition of HER2-positive—that is, women whose breast tumors produce an excess of the HER2 protein—may be too strict. These retrospective studies showed that even women who were HER2-negative benefited from the HER2-targeted agent trastuzumab (Herceptin).
Everolimus Promising in Heavily Pre-treated Metastatic Breast Cancer
January 8, 2021
By CancerConsultants.com
Researchers from Europe have reported that the combination of the mTOR inhibitor everolimus (RAD 001) with Navelbine® (vinorelbine) and Herceptin® (trastuzumab) among heavily pre-treated, Herceptin-resistant metastatic breast cancer patients produced disease stabilization for at least six months in half of all patients. These results were recently presented at the 2008 annual San Antonio Breast Cancer Symposium
Pooled Analysis Shows Low Incidence of Cardiac Complications with Herceptin® for Breast Cancer
January 7, 2021
By CancerConsultants.com
Researchers from Europe have reported that Herceptin® (trastuzumab)-based therapy is associated with a low incidence of cardiac complications in women with HER2-positive breast cancer. These results were presented at the 2008 San Antonio Breast Cancer Symposium December 10-14, 2008.
Study Links Osteoporosis Drugs to Jaw Trouble
January 1, 2021
By Amanda Gardner, Washington Post
The proportion of people taking widely prescribed oral osteoporosis drugs who develop a nasty jaw condition may be much higher than previously thought, a new study suggests.
Previous reports had indicated that the risk of developing osteonecrosis of the jaw (ONJ) from bisphosphonates in pill form were “negligible,” although there was a noted risk in people taking the higher-dose intravenous form of the drug.
But Dr. Parish Sedghizadeh, an assistant professor of clinical dentistry at the University of Southern California School of Dentistry in Los Angeles, said his clinic is seeing one to four new cases a week, compared to one a year in the past. This led him to investigate the phenomenon and publish the findings in the Jan. 1 issue of the Journal of the American Dental Association
Headline News Archive
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- October 2007
- September 2007